Table 3.
Prescriptions For A Single Antipsychotic 300 Subjects
| Medication | Number of subjects prescribed a medication (may be prescribed several formulations)1 | Percent | Number prescribed oral formulation only or long acting formulation only | Median dose (mg) 2 | Mean dose (mg) 2 | 95% CI | Dose range (mg) 2 | Number prescribed higher than 2009 PORT dosing for multi-episode patients | Number prescribed higher than 2009 PORT dosing for first episode patients3 |
|---|---|---|---|---|---|---|---|---|---|
| risperidone | 109 | 36.3% | |||||||
| Oral =107 | 3 5 | 2.9 5 | 2.6, 3.2 | 0.25–7.0 5 | 0 5 | 85 | |||
| Long Acting =1 | 75 | -- | -- | N/A | N/A | ||||
| olanzapine | 51 | 17.0% | Oral = 51 | 15 6 | 16.5 6 | 14.2, 18.7 | 2.5–40 6 | 8 6 | 226 |
| aripiprazole | 35 | 11.7% | Oral = 35 | 10 7 | 10.0 7 | 8.3, 11.7 | 2–20 7 | 0 7 | N/A |
| paliperidone | 30 | 10.0% | |||||||
| Oral =17 | 6 | 5.8 | 4.7, 7.0 | 3–9 | 0 | N/A | |||
| Long Acting = 13 | 136.5 7 | 149.5 7 | 121.9, 177.1 | 117–234 7 | N/A | N/A | |||
| quetiapine | 28 | 9.2% | Oral = 28 | 300 7 | 309.7 7 | 233.5, 386.0 | 20–800 7 | 1 7 | N/A |
| haloperidol | 21 | 7% | |||||||
| Oral =12 | 10 7 | 11.3 7 | 6.4, 16.1 | 3–30 7 | 3 7,8 | N/A | |||
| Long Acting = 4 | 75 | 81.2 | 21.6, 140.9 | 50–125 | N/A | N/A | |||
| ziprasidone | 12 | 4.0% | Oral = 12 | 80 9 | 102.2 9 | 57.8, 146.7 | 40–200 9 | 1 9 | N/A |
| lurasidone | 4 | 1.3% | Oral = 4 | 40 7 | 66.7 7 | 0, 181.4 | 40–120 7 | N/A | N/A |
| asenapine | 2 | 0.7% | Oral = 2 | 10 | 10 | 10 | N/A | N/A | |
| Clozapine | 2 | 0.7% | Oral = 2 | 250 | 250 | 0,885.3 | 200–300 | 0 | N/A |
| thiothixene | 2 | 0.7% | Oral = 2 | 5 | 5 | 5 | 0 | N/A | |
| chlorpromazine | 1 | 0.3% | Oral = 1 | --7 | --7 | --7 | --7 | N/A | |
| fluphenazine | 1 | 0.3% | Oral = 1 | 15 | 15 | 15 | 18 | N/A | |
| loxapine | 1 | 0.3% | Oral = 1 | 40 | 40 | 40 | 0 | N/A | |
| perphenazine | 1 | 0.3% | Oral = 1 | 4 | 4 | 4 | 0 | N/A |
N/A = not applicable
because some subjects were prescribed an oral and a long acting formulation of the same medication, the number of subjects who are prescribed a medication may be larger than the sum of the number prescribed only oral and only long acting formulations;
for subjects prescribed only oral medications or subjects prescribed only long acting medications; dose is total daily dose for oral medications and total dose per month for long acting medications (e.g. 75 mg for a subject receiving two 37.5 mg injections within a month period);
upper daily dose range limit of 15 mg for olanzapine and 5 mg for risperidone based upon 2009 PORT recommendations;
for subjects prescribed only long acting medication;
dosing data not available for 4 subjects;
dosing data not available for 2 subjects;
dosing data not available for 1 subject;
based on 2009 PORT maintenance therapy dose range;
dosing data not available for 3 subjects;